临床试验登记· Genentech, Inc. · ClinicalTrials.gov·· 10 小时前评分19
GDC-4198 联合来曲唑、氟维司群或 giredestrant 一线治疗 HR+/HER2- 晚期乳腺癌 1 期试验启动
A Study to Evaluate the Effects of GDC-4198 in Combination With Letrozole, Fulvestrant, or Giredestrant in Participants With Locally Advanced or Metastatic Hormone Receptor-Positive, HER2-Negatve Breast Cancer
导读
Genentech 于 2026-10-09 登记 1 期试验 NCT07867262，计划入组 165 例局部晚期或转移性 HR+/HER2- 乳腺癌患者，一线评估 GDC-4198 联合来曲唑、氟维司群或 giredestrant 的安全性、药代动力学及初步疗效，预计 2026-12-15 开始招募。
来源：临床试验登记 · clinicaltrials.gov